EANS-News: Intercell provides update on Phase III trial for Travelers' Diarrhea Vaccine Patch

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

research

Vienna (Austria) and Gaithersburg (USA), April 29, 2009 (euro adhoc)
- Intercell AG (VSE: ICLL) today informed regulators, partners and
other parties involved in its planned pivotal Phase III efficacy
study for the investigational Travelers' Diarrhea Vaccine that the
company will wait to initiate this clinical trial until the swine flu
outbreak in Mexico has resolved.

"It is the company´s highest priority to assure the safety of the
individual subjects who would travel to Mexico or Guatemala to
participate in the study. As those travelers today could be at a high
risk of contracting swine flu, it is clear that as a consequence,
Intercell will not initiate initiate this Phase III trial at the
present time.", explained Gerd Zettlmeissl, CEO of Intercell.

In the planned Phase III pivotal efficacy study, known as the "Trek
Study", 1,800 subjects from Europe and the United States are to be
enrolled, vaccinated, and followed during travel to Mexico or
Guatemala for the development of diarrhea.

Intercell will closely monitor the situation and work with local,
national and international health authorities to identify the
appropriate timing for the start of this study. The Company will
continue with the preparatory processes for the study, which will
commence pending resolution of the swine flu situation and is
confident that the current development plans and timelines for the
product should remain unchanged.

About Travelers' Diarrhea

Travelers' Diarrhea is most commonly caused by enterotoxigenic
Escherichia coli (ETEC). An estimated 10 million travelers succumb to
diarrhea illness annually with the highest risk in developing
countries of Latin America, Africa, Asia and the Middle East. The
illness usually results in increased frequency, volume and weight of
stool. Typically, a traveler experiences four to five loose or watery
bowel movements each day, with symptoms of nausea, vomiting,
abdominal cramping, bloating, and general feeling of discomfort
lasting, on average, 3-5 days. During this time, subjects are
considered incapacitated or bedridden, and/or are unable to
participate in planned activities.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market